PremiumRatingsImmunocore Holdings: Strong International Growth and Promising Clinical Trials Drive Buy Recommendation Immunocore reports Q1 EPS 10c, consensus (40c) Immunocore price target lowered to $33 from $38 at Mizuho PremiumThe FlyImmunocore assumed with an Equal Weight at Morgan Stanley Immunocore Holdings: Pioneering HIV Cure with Promising Phase 1 STRIVE Trial Results Immunocore Reports 2024 Growth and Strategic Advances PremiumCompany AnnouncementsImmunocore Holdings Faces Trade Secret Challenges Amid Global Competition Immunocore Holdings: Strong Kimmtrak Sales and Promising Pipeline Support Buy Rating Immunocore Holdings: Sustained Growth and Promising Pipeline Drive Positive Outlook 
